SARS-CoV-2 Serum Viral Load and Prognostic Markers Proposal for COVID-19 Pneumonia in Low-Dose Radiation Therapy Treated Patients
Authors:
- Berta PiquéBPBerta Piqué
- Karla PeñaKPKarla Peña
- Francesc RiuFRFrancesc Riu
- Johana C. AcostaJAJohana C. Acosta
- Laura Torres-RoyoLTLaura Torres-Royo
- Barbara MalaveBMBarbara Malave
- Pablo AraguasPAPablo Araguas
- Rocío BenavidesRBRocío Benavides
- Gabriel de FebrerGFGabriel de Febrer
- Jordi CampsJordi Camps
- Jorge JovenJorge Joven
- Meritxell ArenasMAMeritxell Arenas
Open Access
- 19 January 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 798
Abstract
Several studies have shown that the plasma RNA of SARS-CoV-2 seems to be associated with a worse prognosis of COVID-19. In the present study, we investigated plasma RNA in COVID-19 patients treated with low-dose radiotherapy to determine its prognostic value. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 46 patients with COVID-19 pneumonia treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as laboratory variables, and SARS-CoV-2 serum viral load, were analyzed before LDRT, at 24 h, and one week after treatment. The mean age of the patients was 85 years, and none received any of the SARS-CoV-2 vaccine doses. The mortality ratio during the course of treatment was 33%. RT-qPCR showed amplification in 23 patients. Higher mortality rate was associated with detectable viremia. Additionally, C-reactive protein, lactate dehydrogenase, and aspartate aminotransferase were significant risk factors associated with COVID-19 mortality. Our present findings show that detectable SARS-CoV-2 plasma viremia 24 h before LDRT is significantly associated with increased mortality rates post-treatment, thus downsizing the treatment success.Keywords
Funding Information
- Spanish Society of Radiation Oncology (GICOR-SEOR 2020)
This publication has 36 references indexed in Scilit:
- Immune Response to COVID-19: Can We Benefit from the SARS-CoV and MERS-CoV Pandemic Experience?Pathogens, 2020
- Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19Journal of Infection, 2020
- Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in ChinaHepatology, 2020
- Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational studyAging, 2020
- Radiotherapy of epicondylitis humeriStrahlentherapie und Onkologie, 2018
- SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-κB pathway in human monocyte macrophages in vitroVirus Research, 2009
- T Cell Responses to Whole SARS Coronavirus in HumansThe Journal of Immunology, 2008
- Analysis of Serum Cytokines in Patients with Severe Acute Respiratory SyndromeInfection and Immunity, 2004
- Therapeutic effects of low radiation doses.1994
- RADIOTHERAPY IN THE TREATMENT OF OSTEOARTHROSIS OF THE KNEERheumatology, 1973